LRP5 and atherosclerosis: Conversely, LRP5 expression dysregulation contributes to pathological states such as osteoporosis–pseudoglioma syndrome [18], familial exudative vitreoretinopathy [19], high bone mass disorders [20], atherosclerosis [21], fibrotic renal and kidney diseases [22], and oncological diseases [23].